Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of @entity1 with XXXX .

@entity1 @entity686 @entity69008 @entity8410 @entity5 @entity1252 @entity46544 @entity1988 @entity2717
OBJECTIVES: The interferon (IFN) signature ( @entity2717 ) in @entity1 with @entity1252 ( @entity1252 ) includes over 100 genes induced by type I IFN pathway activation. We developed a method to quantify the @entity2717 using three genes-the @entity2717 ( @entity2717 )-and characterised the clinical characteristics of @entity1 with @entity1252 with different @entity2717 status from multiple clinical trials. METHODS: Blood microarray expression data from a training cohort of @entity1 with @entity1252 confirmed the presence of the @entity2717 and identified surrogate genes. We assayed these genes in a quantitative PCR (qPCR) assay, yielding an @entity2717 from the @entity2717 . The association of @entity2717 status with clinical disease characteristics was assessed in @entity1 with extrarenal lupus and @entity1988 from four clinical trials. RESULTS: Three genes, @entity69008 , EPSTI and @entity46544 , correlated well with the @entity2717 (p>0.96), and composed the @entity2717 qPCR assay. Using the 95th centile for healthy control data, @entity1 with @entity1252 from different studies were classified into two @entity2717 subsets- @entity2717 -Low and @entity2717 -High-that are longitudinally stable over 36   weeks. Significant associations were identified between @entity2717 -High status and higher titres of anti-dsDNA antibodies, presence of anti extractable nuclear antigen autoantibodies, elevated serum @entity8410 of the @entity5 necrosis factor family ( @entity8410 ) levels, and hypocomplementaemia. However, measures of overall clinical disease activity were similar for @entity2717 -High and @entity2717 -Low groups. CONCLUSIONS: The @entity2717 is an @entity2717 biomarker that divides @entity1 with @entity1252 into two subpopulations- @entity2717 -High and @entity2717 -Low-with differing serological manifestations. The @entity2717 does not distinguish between high and low disease activity, but may have utility in identifying @entity1 more likely to respond to treatment(s) targeting @entity686 . CLINICALTRIALSGOV REGISTRATION NUMBER: NCT00962832.
